Background
Methods
Subjects
Antibody testing
Antigen | Sequence |
---|---|
IL1α | LLFFWETHGTKNYFTSVAHPNLFIATKQDYWVCLAGGP |
IL1β | LNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVF |
IL6 | TCLVKIITGLL EFEVYLEYLQNRFESSEEQARAVQM |
IL8 | ELRCQCIKTYSKPFHPKFIKELRVIESGPH |
TNF-α | LIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLS |
Data analysis
Results
Antigen | Number of plates | Mean ± SDa
| CV (%) |
---|---|---|---|
IL1α | 20 | 1.70±0.28 | 16.2 |
IL1β | 23 | 1.12+0.11 | 9.5 |
IL6 | 20 | 1.38+0.12 | 8.6 |
IL8 | 20 | 1.41+0.17 | 11.7 |
TNF-α | 23 | 1.33+0.19 | 13.9 |
Antigens | Patient (n) | Control (n) | Adjusted r
2
|
p
a
|
---|---|---|---|---|
IL1α | ||||
Male | 1.15±0.42 (124) | 1.21±0.39 (131) | -0.002 | 0.228 |
Female | 1.20±0.43 (76) | 1.32±0.39 (89) | 0.009 | 0.083 |
Combined | 1.17±0.42 (200) | 1.26±0.39 (220) | 0.012 | 0.04 |
IL1β | ||||
Male | 0.70±0.28 (124) | 0.77±0.30 (131) | 0.019 | 0.04 |
Female | 0.78±0.31 (76) | 0.80±0.33 (89) | -0.01 | 0.788 |
Combined | 0.73±0.29 (200) | 0.78±0.31 (220) | 0.011 | 0.07 |
IL6 | ||||
Male | 1.13±0.21 (124) | 1.18±0.19 (131) | 0.01 | 0.038 |
Female | 1.11±0.23 (76) | 1.24±0.22 (89) | 0.065 | 0.0008 |
Combined | 1.12±0.22 (200) | 1.20±0.21 (220) | 0.034 | 0.0001 |
IL8 | ||||
Male | 0.97±0.35 (124) | 1.02±0.29 (131) | 0.003 | 0.134 |
Female | 0.94±0.33 (76) | 1.12±0.35 (89) | 0.056 | 0.003 |
Combined | 0.96±0.34 (200) | 1.06±0.32 (220) | 0.021 | 0.002 |
TNF-α | ||||
Male | 0.77±0.40 (124) | 0.95±0.60 (131) | 0.024 | 0.005 |
Female | 0.85±0.48 (76) | 0.95±0.45 (89) | -0.002 | 0.226 |
Combined | 0.80±0.43 (200) | 0.95±0.54 (220) | 0.017 | 0.003 |
Antigen | Before treatment | 3-month treatment | 6-month treatment | |||
---|---|---|---|---|---|---|
r
|
p
a
|
r
|
p
b
|
r
|
p
c
| |
IL1α | -0.024 | 0.762 | -0.005 | 0.978 | -0.477 | 0.039 |
IL1β | -0.011 | 0.888 | -0.030 | 0.875 | -0.278 | 0.250 |
IL6 | -0.052 | 0.517 | -0.191 | 0.304 | -0.519 | 0.023 |
IL8 | -0.089 | 0.266 | -0.239 | 0.196 | -0.400 | 0.090 |
TNF-α | 0.069 | 0.384 | -0.129 | 0.489 | -0.137 | 0.576 |